Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.

Santos I, Ramos C, Mendes C, Sequeira CO, Tomé CS, Fernandes DGH, Mota P, Pires RF, Urso D, Hipólito A, Antunes AMM, Vicente JB, Pereira SA, Bonifácio VDB, Nunes SC, Serpa J.

Nutrients. 2019 Oct 19;11(10). pii: E2523. doi: 10.3390/nu11102523.

2.

Glutathione in Ovarian Cancer: A Double-Edged Sword.

Nunes SC, Serpa J.

Int J Mol Sci. 2018 Jun 26;19(7). pii: E1882. doi: 10.3390/ijms19071882. Review.

3.

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity.

Nunes SC, Ramos C, Lopes-Coelho F, Sequeira CO, Silva F, Gouveia-Fernandes S, Rodrigues A, Guimarães A, Silveira M, Abreu S, Santo VE, Brito C, Félix A, Pereira SA, Serpa J.

Sci Rep. 2018 Jun 22;8(1):9513. doi: 10.1038/s41598-018-27753-y.

4.

Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer.

Nunes SC, Lopes-Coelho F, Gouveia-Fernandes S, Ramos C, Pereira SA, Serpa J.

BMC Evol Biol. 2018 Jun 19;18(1):97. doi: 10.1186/s12862-018-1214-1.

Supplemental Content

Loading ...
Support Center